TWI786303B - 抑制ｃｄｋ4/6活性化合物的晶型及其應用 - Google Patents

抑制ｃｄｋ4/6活性化合物的晶型及其應用 Download PDF

Info

Publication number
TWI786303B
TWI786303B TW108121799A TW108121799A TWI786303B TW I786303 B TWI786303 B TW I786303B TW 108121799 A TW108121799 A TW 108121799A TW 108121799 A TW108121799 A TW 108121799A TW I786303 B TWI786303 B TW I786303B
Authority
TW
Taiwan
Prior art keywords
compound
crystal form
cancer
aforementioned
structural formula
Prior art date
Application number
TW108121799A
Other languages
English (en)
Chinese (zh)
Other versions
TW202016114A (zh
Inventor
王義乾
張春輝
家炳 王
丁列明
Original Assignee
大陸商貝達藥業股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大陸商貝達藥業股份有限公司 filed Critical 大陸商貝達藥業股份有限公司
Publication of TW202016114A publication Critical patent/TW202016114A/zh
Application granted granted Critical
Publication of TWI786303B publication Critical patent/TWI786303B/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TW108121799A 2018-06-21 2019-06-21 抑制ｃｄｋ4/6活性化合物的晶型及其應用 TWI786303B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CNPCT/CN2018/092194 2018-06-21
CN2018092194 2018-06-21

Publications (2)

Publication Number Publication Date
TW202016114A TW202016114A (zh) 2020-05-01
TWI786303B true TWI786303B (zh) 2022-12-11

Family

ID=68983152

Family Applications (1)

Application Number Title Priority Date Filing Date
TW108121799A TWI786303B (zh) 2018-06-21 2019-06-21 抑制ｃｄｋ4/6活性化合物的晶型及其應用

Country Status (14)

Country Link
US (1) US12043622B2 (https=)
EP (1) EP3812386A4 (https=)
JP (1) JP7430656B2 (https=)
KR (1) KR102768666B1 (https=)
CN (2) CN112424202B (https=)
AU (1) AU2019290722B2 (https=)
BR (1) BR112020026052A2 (https=)
EA (1) EA202190036A1 (https=)
IL (1) IL279579B2 (https=)
MX (1) MX2020013847A (https=)
PH (1) PH12020552236A1 (https=)
SG (1) SG11202012858QA (https=)
TW (1) TWI786303B (https=)
WO (1) WO2019242719A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117222411B (zh) * 2021-03-24 2026-03-27 贝达药业股份有限公司 药物组合、包含其的试剂盒及其用途
WO2023131179A1 (zh) * 2022-01-05 2023-07-13 贝达药业股份有限公司 苯并咪唑衍生物或其盐在治疗白血病中的用途
CN115872923B (zh) * 2022-12-29 2023-04-28 成都泰和伟业生物科技有限公司 一种化合物及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016173505A1 (en) * 2015-04-28 2016-11-03 Shanghai Fochon Pharmaceutical Co., Ltd. Certain protein kinase inhibitor
WO2018113771A1 (en) * 2016-12-22 2018-06-28 Betta Pharmaceuticals Co., Ltd Benzimidazole derivatives, preparation methods and uses theirof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105294655B (zh) 2014-07-26 2019-03-15 广东东阳光药业有限公司 Cdk类小分子抑制剂的化合物及其用途
CN104592251B (zh) 2015-01-23 2019-10-01 上海复星医药产业发展有限公司 4-(稠杂环取代氨基)-1h-吡唑-3-甲酰胺类化合物及其用途
WO2017005900A1 (en) 2015-07-08 2017-01-12 F. Hoffmann-La Roche Ag ARYL SULTAM DERIVATIVES AS RORc MODULATORS
CN106608879A (zh) 2015-10-27 2017-05-03 甘李药业股份有限公司 一种蛋白激酶抑制剂及其制备方法和医药用途
WO2017102796A1 (en) 2015-12-16 2017-06-22 F. Hoffmann-La Roche Ag HETEROARYL AMIDE SULTAM DERIVATIVES AS RORc MODULATORS
TWI646094B (zh) 2016-06-01 2019-01-01 大陸商貝達藥業股份有限公司 Crystal form of inhibitory protein kinase active compound and application thereof
WO2019035008A1 (en) 2017-08-15 2019-02-21 Beijing Xuanyi Pharmasciences Co., Ltd. INHIBITORS OF CDK4 / 6 AND THEIR USE

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016173505A1 (en) * 2015-04-28 2016-11-03 Shanghai Fochon Pharmaceutical Co., Ltd. Certain protein kinase inhibitor
WO2018113771A1 (en) * 2016-12-22 2018-06-28 Betta Pharmaceuticals Co., Ltd Benzimidazole derivatives, preparation methods and uses theirof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
期刊 Wang Y, et al. "Design and synthesis of 4-2(2,3-dihydro-1H-benzo[d]pyrrolo[1,2-a]imidazole-7-yl)-N-(5- (piperazin-1-ylmethyl)pyridine-2-amine) as a highly potent and selective cyclin-dependent kinase 4 and 6 inhibitors and the discovery of structure-activity relationships" Bioorganic & Medicinal Chemistry Letters 2018 Mar; 28(5):974-978 *

Also Published As

Publication number Publication date
EP3812386A4 (en) 2022-03-30
IL279579A (en) 2021-03-01
CA3104365A1 (en) 2019-12-26
JP2021529175A (ja) 2021-10-28
EP3812386A1 (en) 2021-04-28
BR112020026052A2 (pt) 2021-03-23
AU2019290722B2 (en) 2023-12-21
IL279579B (en) 2022-10-01
IL279579B2 (en) 2023-02-01
KR102768666B1 (ko) 2025-02-17
CN113861191A (zh) 2021-12-31
KR20210024004A (ko) 2021-03-04
CN112424202A (zh) 2021-02-26
PH12020552236A1 (en) 2021-06-28
TW202016114A (zh) 2020-05-01
CN113861191B (zh) 2023-09-19
US12043622B2 (en) 2024-07-23
MX2020013847A (es) 2021-04-28
AU2019290722A1 (en) 2021-01-28
CN112424202B (zh) 2021-09-17
WO2019242719A1 (zh) 2019-12-26
JP7430656B2 (ja) 2024-02-13
SG11202012858QA (en) 2021-02-25
US20210261546A1 (en) 2021-08-26
EA202190036A1 (ru) 2021-03-24

Similar Documents

Publication Publication Date Title
JP7383652B2 (ja) Ｂ－ｒａｆキナーゼのマレイン酸塩、結晶形、調整方法、及びその使用
CN109311852B (zh) 作为egfr抑制剂的苯胺嘧啶化合物的结晶
WO2023116895A1 (zh) Kras抑制剂的多晶型物及其制备方法和用途
TW202313034A (zh) Egfr抑制劑的鹽、晶型及其組合物和應用
JP2011515370A (ja) ４−アミノ−５−フルオロ−３−［５−（４−メチルピペラジン−１−イル）−１ｈ−ベンズイミダゾール−２−イル］キノリン−２（１ｈ）−オン乳酸塩の結晶形態及び２つの溶媒和物形態
TWI675839B (zh) 一種ｊａｋ激酶抑制劑的硫酸氫鹽的結晶形式及其製備方法
TWI786303B (zh) 抑制ｃｄｋ4/6活性化合物的晶型及其應用
CN105218548A (zh) 一种新型杂环化合物及其制备方法和作为激酶抑制剂的用途
CN113840605B (zh) N-(5-((4-乙基哌嗪-1-基)甲基)吡啶-2-基)-5-氟-4-(3-异丙基-2-甲基-2h-吲唑-5-基)嘧啶-2-胺盐酸盐的结晶形式及其用途
KR20220159457A (ko) Fgfr4 억제제의 염 형태, 결정 형태 및 그 용도
HK40037648A (en) Crystal form of compound for inhibiting the activity of cdk4/6 and use thereof
HK40037648B (en) Crystal form of compound for inhibiting the activity of cdk4/6 and use thereof
CA3104365C (en) Crystal form of compound for inhibiting the activity of cdk4/6 and use thereof
CN111892536A (zh) 取代的喹啉甲酰胺类化合物及其用途
CN112654623B (zh) 新型氮杂三环类化合物的盐型、晶型及其用途
EA043251B1 (ru) Кристаллическая форма соединения для ингибирования активности cdk4/6 и ее применение
WO2021249450A1 (zh) 酪氨酸激酶抑制剂的盐型、晶型、药物组合物及其用途
CN117486813A (zh) N-二取代苯基丙烯酰胺类化合物及其药物组合物和用途
HK1260821B (zh) 作为egfr抑制剂的苯胺嘧啶化合物的结晶